PubRank

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Clinical Trial ID NCT01750580

PubWeight™ 26.71‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01750580

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015 5.10
2 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
3 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
4 Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013 1.29
5 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
6 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
7 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
8 Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015 1.10
9 Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016 1.06
10 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
11 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
12 Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front Immunol 2015 0.94
13 The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016 0.93
14 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
15 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
16 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
17 Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. Front Immunol 2015 0.85
18 Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol 2016 0.79
19 Cancer stem cells and immunoresistance: clinical implications and solutions. Transl Lung Cancer Res 2015 0.79
20 Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy. Front Immunol 2016 0.78
21 Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol 2016 0.77
22 The role of checkpoints in the treatment of GBM. J Neurooncol 2015 0.75
23 Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. BMC Infect Dis 2016 0.75
24 Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Immunotargets Ther 2015 0.75
Next 100